Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Study sponsor: Exelixis
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2012-06Actual
Enrollment · participants222Actual
Source updated2024-02-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.